Wei Qin, Liyan Zhang*
Department of Integrative Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
*Corresponding author: Liyan Zhang
Abstract
Objective: To analyze the clinical efficacy of chemoradiotherapy combined with cell immunotherapy in extensive stage small cell lung cancer. Methods: from March 2022 to 2023, a total of 100 cases were randomized into the control group (n=49) and experimental group (n=51), the control group used conventional chemoradiotherapy, the experimental group with extensive small cell lung cancer chemotherapy combined with cell immunotherapy, comparing the two groups of behavioral ability (Karnofsky, KPS) score, median survival, and 1-year survival rate. Results: Before treatment, there was no significant difference in KPS scores between the two groups (P> 0.05), and after treatment, the KPS score of the experimental group was significantly higher than that of the control group (P <0.05); the median survival and 1-year survival rate of the experimental group were significantly higher than that of the control group (P <0.05). Conclusion: Radiation and chemotherapy combined with extensive stage small cell lung cancer effectively improves the KPS score of patients with extensive stage small cell lung cancer, and improves the median survival period and 1-year survival rate, which is worth popularizing.
References
[1] Wang Mengjuan, Kong Tiantian, Li Hongyu, Liu Chaoying. Clinical effect of duvalizumab plus chemotherapy for extensive stage small cell lung cancer [J]. Chinese Journal of Gerontology, 2023, 43 (23): 5676-5679.
[2] Li Jianguo, Li Shuman, Chen Hui. Efficacy and safety of anlotinib combined with PD-1 inhibitor in broad-stage small cell lung cancer [J]. Journal of Practical Medicine, 2023, 39 (17): 2248-2252.
[3] Jing Yawan, Zeng Hao, Cheng Ruixin, Tian Panwen, Li Yarun. Mechanism of immunoresistance and coping strategies in non-small cell lung cancer [J]. Chinese Journal of Lung Cancer, 2023, 26 (1): 66-77.
[4] Zhang Xiaohan, Zhu Wentao, Ju Wenxiang, Zhao Yingying, Lu Luolan, Shen Aizong. Cost-effectiveness analysis of adliberlizumab plus first-line chemotherapy for broad-stage small cell lung cancer [J]. Chinese Journal of Hospital Pharmacy, 2023, 43 (22): 2545-2550.
[5] He Hua, Hu Wenteng, Ma Minjie, Han Biao. Systematic evaluation of efficacy and Meta-analysis of surgical resection and concurrent chemoradiotherapy in A-N2 stage non-small cell lung cancer after induction chemotherapy or chemoradiotherapy [J]. Chinese Clinical Journal of Thoracic and Cardiovascular Surgery, 2023, 30 (1): 133-139.
[6] Min Xuhong, Wang Shanghu, Sheng Lei, Song Biao, Wang Mengjie, Li Yun, Shi Shanshan, Ma Dongchun. Clinical analysis of carlizumab combined with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2023, 30 (10): 600-605.
How to cite this paper
Clinical Efficacy Analysis of Chemoradiotherapy Combined with Cell Immunotherapy in Broad-stage Small Cell Lung Cancer
How to cite this paper: Wei Qin, Liyan Zhang. (2024) Clinical Efficacy Analysis of Chemoradiotherapy Combined with Cell Immunotherapy in Broad-stage Small Cell Lung Cancer. International Journal of Clinical and Experimental Medicine Research, 8(1), 139-142.
DOI: http://dx.doi.org/10.26855/ijcemr.2024.01.026